恩华药业公告称，公司全资子公司恩华和信与绿叶制药、绿叶嘉奥签署《独家商业合作协议》，获注射 用利培酮微球（II）、棕榈酸帕利哌酮注射液（II）、棕榈酸帕利哌酮注射液三款抗精神病药长效针剂 在中国大陆的独家商业化权益，合作期至2035年12月31日。恩华和信需一次性支付2000万美元授权对 价，2026 - 2035年完成不低于27亿元销售额。若实现承诺销售额，期满后2个月内有优先谈判权。本次 交易不构成关联及重大资产重组。 ...

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. and its subsidiary, Jiangsu Enhua and Xin Medical Marketing Co., Ltd., granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] Group 1 - The three products involved are Risperidone microspheres (Riketu), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all of which are used for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while the group retains ownership of the assets, registration certificates, and all intellectual property rights related to the products [1] - The agreement is set for a duration of ten years, and Enhua will make a one-time non-refundable payment of $20 million as a licensing fee to the group [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. for exclusive commercialization rights of three long-acting injectable antipsychotic products in mainland China [1] Group 1: Agreement Details - The three products involved are Risperidone microspheres (Rykotuo), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all indicated for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while Green Leaf retains ownership of the assets, registration certificates, and all intellectual property rights [1] - The agreement is set for a duration of ten years, with Enhua making a one-time non-refundable payment of $20 million as a licensing fee to Green Leaf [1] Group 2: Market Implications - This collaboration represents a strong partnership between two leading companies in the central nervous system (CNS) field, aiming to deepen the market presence for schizophrenia treatment [1] - The agreement is expected to provide patients with more comprehensive treatment options in the schizophrenia market [1]

Core Viewpoint - Green Leaf Pharmaceutical has signed a collaboration agreement with Jiangsu Enhua Pharmaceutical, granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China, aimed at enhancing treatment options for schizophrenia patients [1][2]. Group 1: Collaboration Agreement - The agreement includes three products: Rykotan (injectable risperidone microspheres), Rybale (paliperidone palmitate injection), and Meibiri (paliperidone palmitate injection), all intended for the treatment of schizophrenia [1]. - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while Green Leaf retains ownership of the assets, registration certificates, and all intellectual property rights [1]. - Enhua will pay a non-refundable licensing fee of $20 million to Green Leaf upon signing the agreement, which has a duration of ten years [1]. Group 2: Market Context and Product Development - Schizophrenia is a chronic and highly recurrent disease, with approximately 8 million patients in China, making treatment adherence a significant challenge [2]. - Long-acting injectable antipsychotics, such as those developed by Green Leaf, significantly improve patient compliance compared to oral formulations, serving as an important strategy to prevent relapse [2]. - Rykotan is noted as China's first independently developed long-acting injectable second-generation antipsychotic, while Rybale is the world's first and only paliperidone long-acting injection with a "one injection in the first month" dosing regimen [2]. Group 3: Strategic Importance - The board believes that the three long-acting injectables create a differentiated product portfolio that addresses the treatment needs of schizophrenia patients across all stages of the disease [3]. - The CNS (central nervous system) sector is a core strategic area for Green Leaf, which possesses a competitive product matrix and platform capabilities in this field [3]. - The collaboration with Enhua aims to deepen the market presence in the CNS sector, particularly enhancing product coverage in primary healthcare centers to help more patients receive standardized treatment and reduce the burden of the disease [3].

本文源自：金融界AI电报 绿叶制药(02186.HK)发布公告，集团的若干附属公司与江苏恩华药业股份有限公司的附属公司江苏恩华 和信医药营销有限公司(恩华)签署合作协议，授予恩华三款抗精神病药长效针剂产品在中国大陆地区的 独家商业化权利。该三款产品分别为瑞可妥(注射用利培酮微球(Ⅱ))、瑞百莱(棕榈酸帕利哌酮注射液 (Ⅱ))和美比瑞(棕榈酸帕利哌酮注射液)，均适用于精神分裂症的治疗。 ...

Group 1 - Green Leaf Pharmaceutical has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical, granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] - The three products include Risperidone microspheres (Riketu), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all aimed at treating schizophrenia [1][2] - Enhua will pay a non-refundable licensing fee of $20 million to Green Leaf Pharmaceutical as part of the agreement, which lasts for ten years [1] Group 2 - Schizophrenia is a chronic, high-recurrence, and highly disabling disease, with approximately 8 million patients in China [2] - Long-acting injectable antipsychotics significantly improve patient compliance compared to oral formulations, making them an important treatment strategy for preventing relapse [2] - The products are developed based on Green Leaf's long-acting and sustained-release technology platform, with Riketu being the first domestically developed second-generation long-acting injectable antipsychotic in China [2] Group 3 - The board believes that the three long-acting injectables form a differentiated product portfolio that addresses the treatment needs of schizophrenia patients at all stages of the disease [3] - CNS (Central Nervous System) is a core strategic area for the company, which aims to accelerate the realization of product pipeline value through strategic partnerships [3] - The collaboration with Enhua will enhance the coverage of these products in primary healthcare centers, helping more patients receive standardized treatment and reduce the burden of the disease [3]

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. and its subsidiary, Jiangsu Enhua Xinyi Pharmaceutical Marketing Co., Ltd., granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] Group 1: Agreement Details - The three products involved are Risperidone microspheres (Rykotuo), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all indicated for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while the group retains ownership of the assets, registration certificates, and all intellectual property rights, as well as responsibility for production and supply [1] - The agreement is set for a duration of ten years, with Enhua making a one-time non-refundable payment of $20 million as a licensing fee to the group [1] Group 2: Strategic Implications - This collaboration represents a strong partnership between two leading companies in the central nervous system (CNS) field, aiming to deepen the market presence in schizophrenia treatment and provide more comprehensive treatment options for patients [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 自願性公告 授予恩華三款抗精神病藥長效針劑產品 於中國大陸的獨家商業化權利 綠葉製藥集團 有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」），董 事 會（「董 事 會」）宣 佈，本 集 團 的 若 干 附 屬 公 司 與 江 蘇 恩 華 藥 業 股 份 有 限 公 司 的 附 屬 公 司 江蘇恩華和信醫藥營銷有限公司（「恩 華」）簽 署 合 作 協 議，授 予 恩 華 三 款 抗 精 神 病 藥 長 效 針 劑 產 品 在 中 國 大 陸 地 區 的 獨 家 商 業 化 權 利。該 三 款 產 品 分 別 為 瑞 可 妥（注 射 用 利 培 酮 微 球（Ⅱ））、瑞 百 萊（ ...

Core Viewpoint - Luye Pharma Group Limited has completed the issuance of 1.5 million exchangeable preferred shares, which can be exchanged for existing shares of Boan Biotechnology, representing approximately 16.15% of Boan's total issued shares [1] Group 1 - The issuer, Luye Geneora Holding Limited, a wholly-owned subsidiary of the company, has allocated and issued 1.5 million exchangeable preferred shares to the subscribers [1] - The exchangeable preferred shares can be converted into shares of Boan Biotechnology without the issuance of any new shares by Boan [1] - Based on the initial exchange price of HKD 11.718, the total number of Boan shares deliverable upon the exchange of all preferred shares is up to 100,486,431 shares [1]

Core Viewpoint - Luye Pharma Group has completed the issuance of 1.5 million exchangeable preferred shares, which can be exchanged for existing shares of Boan Biologics, representing approximately 16.15% of Boan Biologics' total issued shares [1] Group 1 - The issuance of exchangeable preferred shares was finalized on December 12, 2025, according to the terms of the subscription agreement [1] - The issuer, Luye Geneora Holding Limited, a wholly-owned subsidiary of Luye Pharma, allocated and issued the 1.5 million exchangeable preferred shares to the subscribers [1] - The initial exchange price is set at HKD 11.718, allowing for a maximum delivery of 100,486,431 shares of Boan Biologics upon the exchange of all preferred shares [1]